Clinical OMICS

NOV-DEC 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1040438

Contents of this Issue

Navigation

Page 19 of 51

18 Clinical OMICs November/December 2018 www.clinicalomics.com common IT backbone will facilitate sharing of best practices among all members on a continuing basis, often a difficult undertaking for today's oncologists. "Some of our founding practices have built a lot of these processes," noted Shah. "One of the things that we will do in partnership with Flatiron as we identify our best prac- tices—such as treatment regimens and pathways—is we will be able, from a corporate perspective, to push that best practice regimen or set of pharmacy and therapeutic options to every office." Schwartzberg of West Cancer Center, a practice which already has consid- erable IT infrastructure due to the demands of par- ticipating as a member of the Oncology Care Model (OCN), said he anticipates a dynamic sharing of infor- mation among the commu- nity oncology centers that come on board. "We anticipate there will be a partnership between the practices and the OneOncology organization that will allow a free flow of information," said Schwartzberg. "So there will be tools created at the OneOcology level and there will be also be tools that are shared best practices across the other oncology centers." This includes OneOncology using the data generated by its practices to identify gaps in care at the practice level, as well as regional care disparities—and even environmental fac- tors—that could lead to cancer or affect how care is delivered. "There is almost an endless opportunity to ideate around how we will be able to use the data derived from these prac- tices to advance cancer care," Bahl added. Value-Based Care At the heart of the services OneOncology provides to its prac- tice partners—to become more efficient both operationally and in the delivery of care—is the understanding that these efforts will help prepare the oncology centers for value-based reimbursement models. Already applied in the primary care setting and via programs from the Centers for Medicare & Medicaid Services that seek to lower hospital readmissions, OneOncology's founders believe it is only a matter of time before these payment models are broadly applied to cancer care. As Bahl sees it, the three fundamental services OneOn- cology provides—economies of scale, economies of intelli- gence, and access to capital—all play a role in positioning its practices to operate within these payment models. "Economies of scale takes the existing cost advantage com- munity oncology has, generally 60% less than other settings, and allows us to leverage that even further, across operating functions and purchasing functions including pharmaceu- ticals," Bahl noted. "By providing capital to expand opera- tions or add equipment the physician might not have been able to afford, we can improve the quality of care and patient experiences. We believe the cost, quality, patient experience, and access advantages of community oncology position this platform for value-based care better than anyone else." Clinical Trials Access Too often, patients that are served in the community setting— and their doctors—have no consistent method for knowing which clinical trials are recruiting participants that might be of benefit to a specific patient. OneOncology believes their model, with aid of Flatiron's OncoTrials will make these treat- ment options available to patients in the local community. OncoTrials, which uses EMR data, allows practices to automate the process of matching patients with appropriate clinical trials. "One of the things that we have talked about early on is how do we reform and rethink the way clinical research occurs across the organization," Shah said. "How to do I make sure, If I'm a patient in Des Moines, Iowa, or Gettysburg, Penn- sylvania, that I can get access to a clinical trial drug?" But this doesn't apply only to clinical trials, it applies to the provision of a consistent level of care from the first time a patient comes into a OneOncology practice and each subsequent visit. "We are looking at the entire spectrum of the cancer journey, so we are also going to expand what our practices have tradi- tionally done," said Schwarztberg. "Within the context of after diagnosis through survivorship, we are going to make sure the patients get the best care based on pathways, evidence-based care, and making sure patients have a better experience. And we will invest in that to make sure it happens." (continued from previous page) Tracy Bahl, CEO, OneOncology Robin Shah, co-founder, chief marketing officer, OneOncology

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2018